游离/总PSA比值作为转移性去势抵抗性前列腺癌生存生物标志物
该研究在254例新诊断mCRPC患者中分析%fPSA的预后价值,其中161例(63%)%fPSA≥15%。中位随访25.6个月,多变量分析显示%fPSA≥15%与更短OS相关(HR 1.56,95%CI 1.02-2.40;P=0.039);多西他赛治疗亚组中%fPSA≥15%与更差OS相关(HR 1.84,95%CI 1.03-3.26;P=0.038),而接受ARPI治疗者未见关联。
要点
- %fPSA≥15%在mCRPC中与更短总生存独立相关。
- 多西他赛治疗亚组中%fPSA≥15%与更差OS和CSS相关。
- 接受阿比特龙或恩扎卢胺治疗者中%fPSA与结局无关。
核心结论
- 升高的%fPSA可能是mCRPC的不良预后生物标志物,与生化复发研究结果一致,提示存在生物学基础,需验证和机制研究。
研究设计与样本
- 基于mCRPC诊断时前瞻性采集的生物库进行分析,共纳入254例新诊断mCRPC患者,以%fPSA 15%为截断值分层,采用Cox比例风险模型评估%fPSA与OS和CSS的关联。
主要发现
- 254例患者中161例(63%)%fPSA≥15%,中位随访25.6个月,队列中位OS和CSS分别为39.6和43.8个月。
- %fPSA≥15%组中位PSA水平更低(31.30 vs 50.80 ng/mL;P=0.007),其余临床病理和治疗特征与%fPSA<15%组相当。
- 调整PSA后多变量分析显示,%fPSA≥15%与更短OS相关(HR 1.56,95%CI 1.02-2.40;P=0.039)。
- 多西他赛治疗亚组中,%fPSA≥15%与更差OS相关(HR 1.84,95%CI 1.03-3.26;P=0.038)及CSS。
- 接受雄激素受体通路抑制剂(阿比特龙或恩扎卢胺)治疗的患者中,%fPSA与结局无关。
临床怎么用
- 在mCRPC诊断时可检测%fPSA,%fPSA≥15%提示预后较差,尤其在接受多西他赛治疗的患者中可辅助风险分层。
- 对于接受阿比特龙或恩扎卢胺治疗的患者,%fPSA的预后价值有限,需结合其他指标评估。
局限性
- 研究基于单中心生物库,需外部验证。
- %fPSA的生物学机制尚未明确,需机制研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To analyse whether the percentage of free to total prostate-specific antigen (%fPSA) is a prognostic biomarker in metastatic castration-resistant prostate cancer (mCRPC), as novel studies suggest an elevated %fPSA is associated with adverse oncological outcomes for men with biochemical recurrence of prostate cancer. PATIENTS AND METHODS: A biobank prospectively collated at mCRPC diagnosis was analysed for %fPSA. Clinicopathological characteristics, systemic therapies and survival outcomes were recorded. Patients were stratified by a %fPSA cut-off of 15%. Cox proportional hazard models evaluated whether %fPSA was associated with overall survival (OS) and cancer-specific survival (CSS) across the cohort and by treatment. RESULTS: A total of 254 patients analysed with newly diagnosed mCRPC: 161 (63%) men having a %fPSA ≥15%. The median follow-up was 25.6 months. The median cohort OS and CSS was 39.6 and 43.8 months, respectively. Patients with a %fPSA ≥15% had lower median PSA level (31.30 vs 50.80 ng/mL; P = 0.007) and otherwise comparable clinicopathological and treatment profiles to men with a %fPSA <15%. Adjusting for PSA and on multivariable analysis, a %fPSA ≥15% was associated with shorter OS (multivariable hazard ratio [HR] 1.56, 95% confidence interval [CI] 1.02-2.40; P = 0.039). Among men treated with docetaxel, a %fPSA ≥15% was associated with worse OS (HR 1.84, 95% CI 1.03-3.26; P = 0.038) and CSS. Conversely, %fPSA was not associated with outcomes for men receiving androgen receptor pathway inhibitors (abiraterone acetate or enzalutamide). CONCLUSION: An elevated %fPSA appears to be an adverse prognostic biomarker. Findings are consistent with biochemical recurrence studies, suggesting a biological basis. Validation and mechanistic studies are warranted.
引用
- Silagy AW, Woon DTS, Kostos L, et al. Percentage of free to total PSA as a biomarker of survival in metastatic castration-resistant prostate cancer. BJU Int. 2025. PMID: 40275794. doi:10.1111/bju.16751
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。